Market revenue in 2023 | USD 26.4 million |
Market revenue in 2030 | USD 51.6 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 65.15% in 2023. Horizon Databook has segmented the UAE circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of chronic diseases and improvements in healthcare infrastructure are factors anticipated to drive the market growth. Moreover, changes in the regulatory framework of the country provided the opportunity to local players in the market.
In October 2019, VPS Healthcare announced a manufacturing agreement with Apotex Inc. for production of nine generic products for indications such as Lou Gehrig’s disease, hepatitis B, multidrug-resistant bacterial infections, and seizures, among others, for export to North American Market.
The government of UAE is advancing the healthcare infrastructure, which may bridge the gap in health care facilities for providing various treatments to patients. In 2014, the government passed a bill mandating healthcare insurance for UAE citizens. In addition, according to a new regulation passed in 2018 in Abu Dhabi, it is mandatory for all pharmacies to dispense generic medicines as the first choice.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into UAE circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account